tender for e-bid for rate contract cum supply and empanelment of firms for drugs and medicines , fluorouracil inj ip 250 mg/ 5ml [148] , mercaptopurine tablets ip 50 mg [152] , methotrexate tab ip 2.5 mg [154] , vincristine injection ip 1 mg [159] , atropine eye ointment ip 1% [319] , ciprofloxacin ophthalmic ointment usp 0.3% [323] , dacarbazine injection 500 mg ip [529] , inj. ganciclovir sodium 500mg (lyophilized powder for reconstitution) [724] , recombinant f ix 500 iu with diluent [748] , 3rd generation recombinant f viii 250 iu with diluent [749] , brinozolamide 1% w/v and brimonidine tartrate 0.2% w/v ophthalmic suspension [nrd-98] , gatifloxacin 0.30% and prednisolone acetate 1% ophthalmic suspension [nrd-103] , hpmc 0.3% eye drop [nrd-104] , proparacaine 0.5% w/v eye drop usp [nrd-114] , voriconazole 1 % w/v (lyophilized) 30mg eye drop [nrd-119] , chloramphenicol 1%, polymyxin b sulphate (10000 units) and dexamethasone 0.1% sodium phosphate eye ointment [nrd-123] , cabazitaxel injection 60 mg [nrd-167] , carmustine 100 mg inj. ip [nrd-175] , fludarabine phosphate injection 100mg inj. ip [nrd-237] , fludarabine phosphate injection 50mg inj. ip [nrd-238] , methotrexate 1000 mg inj. ip [nrd-289] , inj. methylprednisolone acetate 125 mg i.p. (each vial contains methylprednisolone acetate 125 mg) [nrd-292] , mitomycin 40 mg inj. ip [nrd-297] , omalizumab 150 mg vial inj. [nrd-321] , plerixafor 24 mg inj. [nrd-338] , rasburicase 1.5 mg inj. [nrd-347] , recombinant lh 75iu inj. [nrd-351] , trabectedin 1 mg inj. [nrd- 387] , everolimus 5mg tab./cap. [nrd-530] , everolimus 10mg tab./cap. [nrd-531] , eltrombopag 25mg tablet / capsule [nrd-617] , eltrombopag 50mg tablet / capsule [nrd-618] , nilotinib 150 mg tablet / capsule [nrd-710] , nilotinib 200 mg tablet / capsule [nrd-711] , regorafenib 40 mg tab. [nrd-757] , tegafur 100mg and uracil 224mg capsule [nrd-794] , ulipristal 5mg tab. [nrd-808] glycopegylated extended half life factor viii 1000 iu